

Current list of HBD fusion proteins

Protein X ^a	HBD ^b	regulated as ^c	Refs.
Transcription factors			
APETALA3	GR	transcription factor in <i>Arabidopsis</i>	1
ATF6 α	ER ^e	transcription factor	2
Athb-1	GR	<i>Arabidopsis</i> transcription factor in tobacco	3
Bob1/OBF1	ER ^e	coactivator	4
CCAT (from calcium channel cav1.2)	ER ^e	transcription factor	5
C/EBP	ER, GR	transcription factor	6
C/EBP β (=NF-M)	ER	transcription factor, differentiation factor	7
CLOCK	GR	transcription factor	8
CONSTANS	GR	putative transcription factor in arabidopsis	9
E1A	GR	transcription factor	10
E1A	ER	oncoprotein	11
E2F-1, -2, -3	ER	transcription factor	12
E2A	ER ^e	transcription factor	13
E7 (of HPV16)	ER	oncoprotein	9
EBNA2	ER ^e	oncoprotein	14
EBNA3C	ER ^e	oncoprotein	15
Erm (Ets family)	ER	transcription factor	16
c-Fos, v-Fos, FosB-L, FosB-S	ER, GR	oncoprotein, transcription factor	17,18
FOXO3a	ER	transcription factor	19
Gal4	ER, GR, MR, PR	transcription factor in yeast, tissue culture cells and zebra fish	20, 21, i
Gal4-KRAB	PR ^e	transcriptional repressor	22
Gal4-p65 ^d	PR ^e	transcription factor	23
Gal4-VP16	ER, GR, PR ^e	transcription factor in yeast, in tissue culture cells, transgenic mice, <i>Xenopus</i> , <i>Drosophila</i> and plants	22,24-30
GATA-1, -2, -3	ER	transcription factor, promoter of proliferation	31
Gcn4	ER, MR	transcription factor	32
Gli	ER	transcription factor	33

Hoxa9	ER	transcription factor	34
Hoxb8	ER	transcription factor	34
IRF-1	ER	transcription factor	35
c-Jun	ER	transcription factor	36
JunD	ER	transcription factor	37
v-Jun (DBD f)	ER	as DNA binding factor	38
Klf1	ER e	transcription factor	39
LexA-p65 d	PR e	transcription factor in fish	40
LexA-VP16	ER	transcription factor in yeast and plants	i, 41,42
MT-MC1	ER e	transcription factor	43
v-Myb	ER	transcription factor	44
c-Myc	ER, GR	oncoprotein	45
MyoD	ER, TR, GR	transcription factor in tissue culture and frog embryos	46,47
Notch (ic)	ER	transcription factor	48
p53	ER	regulator of proliferation	49,50
Pax3-FKHR	ER e	transcription factor	51
Pax5	ER	transcription factor	52
Pax7	ER e	transcription factor	53
PU.1	ER	transcription factor	54
QF	GR	<i>Neurospora</i> transcription factor in <i>C. elegans</i>	55
R (of maize)	GR	transcription factor in <i>Arabidopsis</i>	56
v-Rel, c-Rel	ER	oncoprotein, transcription factor	57,58
RUNX1	ER e	transcription factor	59
Snail	ER e	transcription factor	60
Stat1, Stat5A, Stat5B	ER	transcription factor	61
Stat6	ER e	transcription factor	61,62
TLS-CHOP	ER	oncoprotein	63
Twist	ER e	transcription factor	60
Xbra	GR	transcription factor in frog embryos	64
Zinc finger TFs	ER e , PR	artificial transcription factors	65,66
Zta	ER e	activator of EBV replication	67
Kinases			
Abl	ER, GR	oncoprotein, tyrosine kinase	68
Akt (=PKB)	ER e	serine / threonine kinase	69
erbB1	ER	tyrosine kinase	g
MEK1	ER e	oncoprotein, dual kinase	70
MEKK3	ER	activation of SAPK pathway	71
Raf-1	ER, AR	oncoprotein, serine / threonine kinase	72,73

A-Raf, B-Raf Ste11 Src	ER ER, MR, PR ER	oncoproteins serine / threonine kinase in yeast tyrosine kinase	74 75 and i g; see also ref. 76
Split Cas9 Chimeric dCas9 and dCas9- targeted synthetic activators	ER <i>e</i> , GR ER <i>e</i>	synthetic activator synthetic activator	77 78
Recombinases & nucleases			
AsiSI	ER <i>e</i>	restriction enzyme in tissue culture cells	79
Cas9	ER <i>e</i>	excision of intein from Cas9	80
Cas9	ER <i>e</i>	endonuclease	78,81
Split Cas9	ER <i>e</i> , GR	endonuclease	77
Cre <i>j</i>	ER <i>e</i> , PR <i>e</i> , GR <i>e</i> , AR <i>e</i>	recombinase in tissue culture cells, transgenic mice and yeast	82-90
Flp	ER, GR, AR	recombinase in tissue culture cells and yeast	91,92
I-Ppol	ER <i>e</i>	homing endonuclease	93
I-SceI	GR	homing endonuclease	94
<i>piggyBac</i> transposase	ER <i>e</i>	in tissue culture cells	95
Miscellaneous			
BLNK	ER <i>e</i>	adaptor protein	96
β -catenin	ER <i>e</i>	signaling molecule	97
Cdc13	ER	cyclin (in <i>S. pombe</i>)	98
Fas	ER, RAR	apoptosis	99
β -galactosidase	ER, PR	α -complementation in yeast	100
G α_q	ER <i>e</i>	G protein	101
HDAC3	ER <i>e</i>	histone deacetylase	102
Intein fusion	ER <i>e</i>	protein splicing	103,104
p16-INK4A	ER	CDK inhibitor	105
Psf2	ER	DNA replication (in <i>S. pombe</i>)	98
Ras	ER	in yeast	106
Ras G12V	ER <i>e</i>	oncogene transformation	107
Rep (of AAV)	ER, PR <i>e</i>	replication, integration	h, 108
Rev (of HIV)	GR	transactivation (RNA-binding protein)	109
Rex (of HTLV-1)	ER	Rex functions, localization	110
SIRT1	ER <i>e</i>	Protein deacetylase	111

Telomerase	ER ^e	telomerase function	112
Thymidylate synthase	ER ^e	enzyme activity and growth in <i>E. coli</i>	113

Footnotes

- a* Proteins were alphabetically grouped into different classes.
- b* HBDs were from the following receptors: AR, ER, GR, MR, PR, RAR, and TR, androgen, estrogen, glucocorticoid, mineralocorticoid, progesterone, retinoic acid, and thyroid receptors, respectively.
- c* Unless indicated assays were done in vertebrate tissue culture cells.
- d* Contains activation domain of the NF κ B component p65.
- e* Mutant HBDs that only (or also) respond to antihormones were used in some experiments.
- f* DBD, DNA binding domain.
- g* J. M. Bishop, personal communication.
- h* A. Salvetti, personal communication.
- i* Picard lab, unpublished results.
- j* High level expression, at least in some tissues or cells, can lead to significant constitutive activity (refs. 114,115).

Reviews:

Picard, D. (2000). Posttranslational regulation of proteins by fusions to steroid-binding domains. *Methods Enzymol.* 327, 385-401.

Use of ER α HBD fusions in the mouse: Whitfield, J., Littlewood, T., Evan, G. I., and Soucek, L. (2015). The estrogen receptor fusion system in mouse models: a reversible switch. *Cold Spring Harb. Protoc.* 2015, 227-234.

References

1. Sablowski, R. W. & Meyerowitz, E. M. A homolog of *NO APICAL MERISTEM* is an immediate target of the floral homeotic genes *APETALA3/PISTILLATA*. *Cell* **92**, 93-103 (1998).
2. Thuerauf, D. J., Marcinko, M., Belmont, P. J. & Glembotski, C. C. Effects of the isoform-specific characteristics of ATF6 α and ATF6 β on endoplasmic reticulum stress response gene expression and cell viability. *J. Biol. Chem.* **282**, 22865-22878 (2007).
3. Aoyama, T. *et al.* Ectopic expression of the Arabidopsis transcriptional activator Athb-1 alters leaf cell fate in tobacco. *Plant Cell* **7**, 1773-1785 (1995).
4. Laumen, H., Nielsen, P. J. & Wirth, T. The BOB.1 / OBF.1 co-activator is essential for octamer-dependent transcription in B cells. *Eur. J. Immunol.* **30**, 458-469 (2000).
5. Gomez-Ospina, N., Tsuruta, F., Barreto-Chang, O., Hu, L. & Dolmetsch, R. The C terminus of the L-type voltage-gated calcium channel $ca(v)1.2$ encodes a transcription factor. *Cell* **127**, 591-606 (2006).
6. Umek, R. M., Friedman, A. D. & McKnight, S. L. CCAAT-enhancer binding protein: A component of a differentiation switch. *Science* **251**, 288-292 (1991).
7. Müller, C., Kowenz-Leutz, E., Grieser-Ade, S., Graf, T. & Leutz, A. NF-M (chicken C/EBP beta) induces eosinophilic differentiation and apoptosis in a hematopoietic progenitor cell line. *EMBO J.* **14**, 6127-6135 (1995).
8. McDonald, M. J. & Rosbash, M. Microarray analysis and organization of circadian gene expression in *Drosophila*. *Cell* **107**, 567-578 (2001).
9. Simon, R., Igeno, M. I. & Coupland, G. Activation of floral meristem identity genes in Arabidopsis. *Nature* **384**, 59-62 (1996).
10. Picard, D., Salser, S. J. & Yamamoto, K. R. A movable and regulable inactivation function within the steroid binding domain of the glucocorticoid receptor. *Cell* **54**, 1073-1080 (1988).
11. Spitkovsky, D. *et al.* Modulation of cyclin gene expression by adenovirus E1A in a cell line with E1A-dependent conditional proliferation. *J. Virol.* **68**, 2206-2214 (1994).
12. Vigo, E. *et al.* CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. *Mol. Cell. Biol.* **19**, 6379-6395 (1999).
13. Jones, M. E., Kondo, M. & Zhuang, Y. A tamoxifen inducible knock-in allele for investigation of E2A function. *BMC Dev. Biol.* **9**, 51 (2009).
14. Zhao, B. *et al.* RNAs induced by Epstein-Barr virus nuclear antigen 2 in lymphoblastoid cell lines. *Proc. Natl. Acad. Sci. USA* **103**, 1900-1905 (2006).
15. Maruo, S. *et al.* Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. *Proc. Natl. Acad. Sci. USA* **103**, 19500-19505 (2006).
16. Pelczar, H., Albagli, O., Chotteau-Lelièvre, A., Damour, I. & de Launoit, Y. A conditional version of the Ets transcription factor Erm by fusion to the ligand binding domain of the oestrogen receptor. *Biochem. Biophys. Res. Commun.* **239**, 252-256 (1997).
17. Schuermann, M., Hennig, G. & Müller, R. Transcriptional activation and transformation by chimaeric Fos-estrogen receptor proteins: altered properties as a consequence of gene fusion. *Oncogene* **8**, 2781-2790 (1993).
18. Superti-Furga, G., Bergers, G., Picard, D. & Busslinger, M. Hormone-dependent transcriptional regulation and cellular transformation by Fos-steroid receptor fusion proteins. *Proc. Natl. Acad. Sci. USA* **88**, 5114-5118 (1991).
19. Tran, H. *et al.* DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. *Science* **296**, 530-534 (2002).

20. Picard, D. in *Nuclear receptors: a practical approach* (ed. Picard, D.) 261-274 (Oxford University Press, Oxford, 1999).
21. Gerety, S. S. *et al.* An inducible transgene expression system for zebrafish and chick. *Development* **140**, 2235-2243 (2013).
22. Wang, Y., Xu, J., Pierson, T., O'Malley, B. & Tsai, S. Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator. *Gene Ther.* **4**, 432-441 (1997).
23. Burcin, M. M., Schiedner, G., Kochanek, S., Tsai, S. Y. & O'Malley, B. W. Adenovirus-mediated regulable target gene expression *in vivo*. *Proc. Natl. Acad. Sci. USA* **96**, 355-360 (1999).
24. Wang, Y., O'Malley, B. W., Jr., Tsai, S. Y. & O'Malley, B. W. A regulatory system for use in gene transfer. *Proc. Natl. Acad. Sci. USA* **91**, 8180-8184 (1994).
25. Louvion, J.-F., Havaux-Copf, B. & Picard, D. Fusion of GAL4-VP16 to a steroid binding domain provides a tool for gratuitous induction of galactose-responsive genes in yeast. *Gene* **131**, 129-134 (1993).
26. Braselmann, S., Graninger, P. & Busslinger, M. A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins. *Proc. Natl. Acad. Sci. USA* **90**, 1657-1661 (1993).
27. Aoyama, T. & Chua, N.-H. A glucocorticoid-mediated transcriptional induction system in transgenic plants. *Plant J.* **11**, 605-612 (1997).
28. Wang, Y., DeMayo, F. J., Tsai, S. Y. & O'Malley, B. W. Ligand-inducible and liver-specific target gene expression in transgenic mice. *Nat. Biotechnol.* **15**, 239-243 (1997).
29. Das, B. & Brown, D. D. Controlling transgene expression to study *Xenopus laevis* metamorphosis. *Proc. Natl. Acad. Sci. USA* **101**, 4839-4842 (2004).
30. Nicholson, L. *et al.* Spatial and temporal control of gene expression in *Drosophila* using the inducible GeneSwitch GAL4 system. I. Screen for larval nervous system drivers. *Genetics* **178**, 215-234 (2008).
31. Briegel, K. *et al.* Ectopic expression of a conditional GATA-2/estrogen receptor chimera arrests erythroid differentiation in a hormone-dependent manner. *Genes Dev.* **7**, 1097-1109 (1993).
32. Fankhauser, C. P., Briand, P.-A. & Picard, D. The hormone binding domain of the mineralocorticoid receptor can regulate heterologous activities *in cis*. *Biochem. Biophys. Res. Commun.* **200**, 195-201 (1994).
33. Louro, I. D. *et al.* Comparative gene expression profile analysis of GLI and c-MYC in an epithelial model of malignant transformation. *Cancer Res.* **62**, 5867-5873 (2002).
34. Wang, G. G. *et al.* Quantitative production of macrophages or neutrophils *ex vivo* using conditional Hoxb8. *Nat. Methods* **3**, 287-293 (2006).
35. Kroger, A. *et al.* Growth suppression of the hepatocellular carcinoma cell line Hepa1-6 by an activatable interferon regulatory factor-1 in mice. *Cancer Res.* **61**, 2609-2617. (2001).
36. Fialka, I. *et al.* The estrogen-dependent c-JunER protein causes a reversible loss of mammary epithelial cell polarity involving a destabilization of adherens junctions. *J. Cell Biol.* **132**, 1115-1132 (1996).
37. Francis, M. K., Phinney, D. G. & Ryder, K. Analysis of the hormone-dependent regulation of a JunD-estrogen receptor chimera. *J. Biol. Chem.* **270**, 11502-11513 (1995).
38. Kruse, U., Iacovoni, J. S., Goller, M. E. & Vogt, P. K. Hormone-regulatable neoplastic transformation induced by a Jun-estrogen receptor chimera. *Proc. Natl. Acad. Sci. USA* **94**, 12396-12400 (1997).

39. Coghill, E. *et al.* Erythroid Kruppel-like factor (EKLF) coordinates erythroid cell proliferation and hemoglobinization in cell lines derived from EKLF null mice. *Blood* **97**, 1861-1868 (2001).
40. Emelyanov, A. & Parinov, S. Mifepristone-inducible LexPR system to drive and control gene expression in transgenic zebrafish. *Dev. Biol.* **320**, 113-121 (2008).
41. Zuo, J., Niu, Q.-W. & Chua, N.-H. An estrogen receptor-based transactivator XVE mediates highly inducible gene expression in transgenic plants. *Plant J.* **24**, 265-273 (2000).
42. Ottoz, D. S., Rudolf, F. & Stelling, J. Inducible, tightly regulated and growth condition-independent transcription factor in *Saccharomyces cerevisiae*. *Nucleic Acids Res.* **42**, e130 (2014).
43. Rogulski, K. R., Cohen, D. E., Corcoran, D. L., Benos, P. V. & Prochownik, E. V. Dereglulation of common genes by c-Myc and its direct target, MT-MC1. *Proc. Natl. Acad. Sci. USA* **102**, 18968-18973 (2005).
44. Burk, O. & Klempnauer, K.-H. Estrogen-dependent alterations in differentiation state of myeloid cells caused by a v-myb/estrogen receptor fusion protein. *EMBO J.* **10**, 3713-3719 (1991).
45. Eilers, M., Picard, D., Yamamoto, K. R. & Bishop, J. M. Chimeras of the MYC oncoprotein and steroid receptors cause hormone-dependent transformation of cells. *Nature* **340**, 66-68 (1989).
46. Hollenberg, S. M., Cheng, P. F. & Weintraub, H. Use of a conditional MyoD transcription factor in studies of MyoD trans-activation and muscle determination. *Proc. Natl. Acad. Sci. USA* **90**, 8028-8032 (1993).
47. Kolm, P. J. & Sive, H. L. Efficient hormone-inducible protein function in *Xenopus laevis*. *Dev. Biol.* **171**, 267-272 (1995).
48. Ronchini, C. & Capobianco, A. J. Notch(ic)-ER chimeras display hormone-dependent transformation, nuclear accumulation, phosphorylation and CBF1 activation. *Oncogene* **19**, 3914-3924 (2000).
49. Roemer, K. & Friedmann, T. Modulation of cell proliferation and gene expression by a p53-estrogen receptor hybrid protein. *Proc. Natl. Acad. Sci. USA* **90**, 9252-9256 (1993).
50. Sengupta, S., Ralhan, R. & Wasyluk, B. Tumour regression in a ligand inducible manner mediated by a chimeric tumour suppressor derived from p53. *Oncogene* **19**, 337-350 (2000).
51. Ayyanathan, K. *et al.* Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. *Cancer Res.* **60**, 5803-5814. (2000).
52. Nutt, S. L., Morrison, A. M., Dorfler, P., Rolink, A. & Busslinger, M. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. *EMBO J.* **17**, 2319-2333 (1998).
53. Mayran, A. *et al.* Pioneer factor Pax7 deploys a stable enhancer repertoire for specification of cell fate. *Nat. Genet.* **50**, 259-269 (2018).
54. Huang, G. *et al.* PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. *Nat. Genet.* **40**, 51-60 (2008).
55. Monsalve, G. C., Yamamoto, K. R. & Ward, J. D. A new tool for inducible gene expression in *Caenorhabditis elegans*. *Genetics* **211**, 419-430 (2019).
56. Lloyd, A. M., Schena, M., Walbot, V. & Davis, R. W. Epidermal cell fate determination in *Arabidopsis*: patterns defined by a steroid-inducible regulator. *Science* **266**, 436-439 (1994).
57. Boehmelt, G. *et al.* Hormone-regulated v-rel estrogen receptor fusion protein: reversible induction of cell transformation and cellular gene expression. *EMBO J.* **11**, 4641-4652 (1992).

58. Zurovec, M., Petrenko, O., Roll, R. & Enrietto, P. J. A chicken c-Rel-estrogen receptor chimeric protein shows conditional nuclear localization, DNA binding, transformation and transcriptional activation. *Oncogene* **16**, 3133-3142 (1998).
59. Wotton, S. *et al.* Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. *Oncogene* **27**, 5856-5866 (2008).
60. Mani, S. A. *et al.* The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* **133**, 704-715 (2008).
61. Milocco, L. H., Haslam, J. A., Rosen, J. & Seidel, H. M. Design of conditionally active STATs: insights into STAT activation and gene regulatory function. *Mol. Cell. Biol.* **19**, 2913-2920 (1999).
62. Kamogawa, Y. *et al.* A conditionally active form of STAT6 can mimic certain effects of IL-4. *J. Immunol.* **161**, 1074-1077 (1998).
63. Zinszner, H., Albalat, R. & Ron, D. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. *Genes Dev.* **8**, 2513-2526 (1994).
64. Tada, M., O'Reilly, M. A. & Smith, J. C. Analysis of competence and of Brachyury autoinduction by use of hormone- inducible Xbra. *Development* **124**, 2225-2234 (1997).
65. Beerli, R. R., Schopfer, U., Dreier, B. & Barbas, C. F., 3rd. Chemically regulated zinc finger transcription factors. *J. Biol. Chem.* **275**, 32617-32627 (2000).
66. Mclsaac, R. S., Gibney, P. A., Chandran, S. S., Benjamin, K. R. & Botstein, D. Synthetic biology tools for programming gene expression without nutritional perturbations in *Saccharomyces cerevisiae*. *Nucleic Acids Res.* **42**, e48 (2014).
67. Johannsen, E. *et al.* Proteins of purified Epstein-Barr virus. *Proc. Natl. Acad. Sci. USA* **101**, 16286-16291 (2004).
68. Jackson, P., Baltimore, D. & Picard, D. Hormone-conditional transformation by fusion proteins of c-Abl and its transforming variants. *EMBO J.* **12**, 2809-2819 (1993).
69. Kohn, A. D. *et al.* Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. *J. Biol. Chem.* **273**, 11937-11943 (1998).
70. Greulich, H. & Erikson, R. L. An analysis of Mek1 signaling in cell proliferation and transformation. *J. Biol. Chem.* **273**, 13280-13288 (1998).
71. Ellinger-Ziegelbauer, H., Brown, K., Kelly, K. & Siebenlist, U. Direct activation of the stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways by an inducible mitogen-activated protein kinase/erk kinase kinase 3 (MEKK) derivative. *J. Biol. Chem.* **272**, 2668-2674 (1997).
72. Samuels, M. L., Weber, M. J., Bishop, J. M. & McMahon, M. Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human Raf-1 protein kinase. *Mol. Cell. Biol.* **13**, 6241-6252 (1993).
73. Sewing, A., Wiseman, B., Lloyd, A. C. & Land, H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. *Mol. Cell. Biol.* **17**, 5588-5597 (1997).
74. Pritchard, C. A., Samuels, M. L., Bosch, E. & McMahon, M. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. *Mol. Cell. Biol.* **15**, 6430-6442 (1995).
75. Mattioni, T., Louvion, J.-F. & Picard, D. in *Protein expression in animal cells* (ed. Roth, M.) 335-352 (Academic Press, 1994).
76. Mattioni, T., Mayer, B. J. & Picard, D. Growth inhibition by Abl requires an interplay of its SH2 and tyrosine kinase domains. *FEBS Lett.* **390**, 170-174 (1996).
77. Nguyen, D. P. *et al.* Ligand-binding domains of nuclear receptors facilitate tight control of split CRISPR activity. *Nat. Commun.* **7**, 12009 (2016).
78. Lu, J. *et al.* Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing. *Nucleic Acids Res.* **46**, e25 (2018).

79. Iacovoni, J. S. *et al.* High-resolution profiling of γ H2AX around DNA double strand breaks in the mammalian genome. *EMBO J.* **29**, 1446-1457 (2010).
80. Davis, K. M., Pattanayak, V., Thompson, D. B., Zuris, J. A. & Liu, D. R. Small molecule-triggered Cas9 protein with improved genome-editing specificity. *Nat. Chem. Biol.* **11**, 316-318 (2015).
81. Oakes, B. L. *et al.* Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch. *Nat. Biotechnol.* **34**, 646-651 (2016).
82. Metzger, D., Clifford, J., Chiba, H. & Chambon, P. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. *Proc. Natl. Acad. Sci. USA* **92**, 6991-6995 (1995).
83. Feil, R., Wagner, J., Metzger, D. & Chambon, P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. *Biochem. Biophys. Res. Commun.* **237**, 752-757 (1997).
84. Kellendonk, C. *et al.* Regulation of Cre recombinase activity by the synthetic steroid RU486. *Nucleic Acids Res.* **24**, 1404-1411 (1996).
85. Brocard, J. *et al.* Spatio-temporally controlled site-specific somatic mutagenesis in the mouse. *Proc. Natl. Acad. Sci. USA* **94**, 14559-14563 (1997).
86. Feil, R. *et al.* Ligand-activated site-specific recombination in mice. *Proc. Natl. Acad. Sci. USA* **93**, 10887-10890 (1996).
87. Zhang, Y. *et al.* Inducible site-directed recombination in mouse embryonic stem cells. *Nucleic Acids Res.* **24**, 543-548 (1996).
88. Brocard, J., Feil, R., Chambon, P. & Metzger, D. A chimeric Cre recombinase inducible by synthetic, but not by natural ligands of the glucocorticoid receptor. *Nucleic Acids Res.* **26**, 4086-4090 (1998).
89. Kaczmarczyk, S. J. & Green, J. E. Induction of cre recombinase activity using modified androgen receptor ligand binding domains: a sensitive assay for ligand-receptor interactions. *Nucleic Acids Res.* **31**, e86 (2003).
90. Cheng, T. H., Chang, C. R., Joy, P., Yablok, S. & Gartenberg, M. R. Controlling gene expression in yeast by inducible site-specific recombination. *Nucleic Acids Res.* **28**, E108 (2000).
91. Logie, C. & Stewart, A. F. Ligand-regulated site-specific recombination. *Proc. Natl. Acad. Sci. USA* **92**, 5940-5944 (1995).
92. Nichols, M., Rientjes, J. M. J., Logie, C. & Stewart, A. F. FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists. *Mol. Endocrinol.* **11**, 950-961 (1997).
93. Berkovich, E., Monnat, R. J., Jr. & Kastan, M. B. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. *Nat. Cell Biol.* **9**, 683-690 (2007).
94. Soutoglou, E. *et al.* Positional stability of single double-strand breaks in mammalian cells. *Nat. Cell Biol.* **9**, 675-682 (2007).
95. Cadinanos, J. & Bradley, A. Generation of an inducible and optimized piggyBac transposon system. *Nucleic Acids Res.* **35**, e87 (2007).
96. Schebesta, M., Pfeffer, P. L. & Busslinger, M. Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. *Immunity* **17**, 473-485 (2002).
97. Lo Celso, C., Prowse, D. M. & Watt, F. M. Transient activation of beta-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours. *Development* **131**, 1787-1799 (2004).
98. Bøe, C. A. *et al.* Rapid regulation of protein activity in fission yeast. *BMC Cell Biol.* **9**, 23 (2008).

99. Takebayashi, H. *et al.* Hormone-induced apoptosis by Fas-nuclear receptor fusion proteins: novel biological tools for controlling apoptosis in vivo. *Cancer Res.* **56**, 4164-4170 (1996).
100. Abbas-Terki, T. & Picard, D. α -complemented β -galactosidase. An *in vivo* model substrate for the molecular chaperone heat-shock protein 90 in yeast. *Eur. J. Biochem.* **266**, 517-523 (1999).
101. Lu, Z., Jiang, Y. P., Ballou, L. M., Cohen, I. S. & Lin, R. Z. Gq α inhibits cardiac L-type Ca²⁺ channels through phosphatidylinositol 3-kinase. *J. Biol. Chem.* **280**, 40347-40354 (2005).
102. Escaffit, F. *et al.* Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression. *Mol. Cell. Biol.* **27**, 554-567 (2007).
103. Buskirk, A. R., Ong, Y.-C., Gartner, Z. J. & Liu, D. R. Directed evolution of ligand dependence: small-molecule-activated protein splicing. *Proc. Natl. Acad. Sci. USA* **101**, 10505-10510 (2004).
104. Skretas, G. & Wood, D. W. Regulation of protein activity with small-molecule-controlled inteins. *Protein Sci.* **14**, 523-532 (2005).
105. Kanuma. A new system for regulated functional gene expression for gene therapy applications: Nuclear delivery of a p16INK4A-estrogen receptor carboxy terminal fusion protein only in the presence of estrogen. *Int. J. Oncol.* **36**, 905-912 (2010).
106. Kohler, F., Zimmermann, A., Hager, M. & Sippel, A. E. A genetic, non-transcriptional assay for nuclear receptor ligand binding in yeast. *Gene* **337**, 113-119 (2004).
107. De Vita, G. *et al.* Dose-dependent inhibition of thyroid differentiation by RAS oncogenes. *Mol. Endocrinol.* **19**, 76-89 (2005).
108. Rinaudo, D., Lamartina, S., Roscilli, G., Ciliberto, G. & Toniatti, C. Conditional site-specific integration into human chromosome 19 by using a ligand-dependent chimeric adeno-associated virus/Rep protein. *J. Virol.* **74**, 281-294 (2000).
109. Hope, T. J., Huang, X. J., McDonald, D. & Parslow, T. G. Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif. *Proc. Natl. Acad. Sci. USA* **87**, 7787-7791 (1990).
110. Rehberger, S. *et al.* The activation domain of a hormone inducible HTLV-1 Rex protein determines colocalization with the nuclear pore. *Exp. Cell Res.* **233**, 363-371 (1997).
111. Clark-Knowles, K. V. *et al.* Reversible modulation of SIRT1 activity in a mouse strain. *PLoS ONE* **12**, e0173002 (2017).
112. Jaskelioff, M. *et al.* Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. *Nature* **469**, 102-106 (2011).
113. Skretas, G. & Wood, D. W. A bacterial biosensor of endocrine modulators. *J. Mol. Biol.* **349**, 464-474 (2005).
114. Buelow, B. & Scharenberg, A. M. Characterization of parameters required for effective use of tamoxifen-regulated recombination. *PLoS ONE* **3**, e3264 (2008).
115. Liu, Y. *et al.* Tamoxifen-independent recombination in the *RIP-CreER* mouse. *PLoS ONE* **5**, e13533 (2010).